Hamostaseologie 2002; 22(04): 154-160
DOI: 10.1055/s-0037-1619558
Research Articles
Schattauer GmbH

Diagnostik und Therapie der Thrombophlebitis unter besonderer Berücksichtigung niedermolekularer Heparine

Diagnosis and therapy of thrombophlebitis with special consideration of low molecular weight heparin
H. Partsch
1   Dermatologische Abteilung des Wilhelminenspitals der Stadt Wien (Emeritierter Vorstand: Prof. Dr. Hugo Partsch)
› Author Affiliations
Further Information

Publication History

Publication Date:
27 December 2017 (online)

Zusammenfassung

Die klinische Diagnose der oberflächlichen Thrombophlebitis ist charakterisiert durch das Auftreten von schmerzhaften und entzündeten Strängen im Bereich von oberflächlichen Venen und Varizen. Eine Duplexsonographie wird empfohlen, um eine asymptomatische tiefe Venenthrombose auszuschließen, die in ca. 20% vorliegen kann, und um potentielle Eintrittspforten des thrombotischen Prozesses in tiefe Venen (z. B. Mündung von Vena saphena magna und parva) abzuklären. Die klassische Behandlung basiert auf einer festen Kompression sowie Gehübungen. Inzisionen mit Expression von Gerinnseln sowie entzündungshemmende Medikamente können Schmerzen und Entzündung lindern. Wenn die Phlebitis auch den Oberschenkel und besonders die proximalen Anteile der Vena saphena magna betrifft, kann eine Mündungsligatur und eine lokale Thrombektomie überlegt werden, bevorzugt unter ambulanten Bedingungen. Neue Daten einer randomisierten kontrollierten Studie beweisen die Wirksamkeit von unfraktioniertem Heparin in der Dosierung von zweimal 12 500 I.E. s. c. bei dieser Indikation.

Aufgrund einer weiteren randomisierten kontrollierten Studie kann niedermolekulares Heparin (NMH) die Entwicklung von thromboembolischen Komplikationen und die relativ häufige Ausbreitung der Thromben in den oberflächlichen Venen verzögern. Therapeutische Dosen scheinen effektiver zu sein als prophylaktische. Während die herkömmliche Behandlung mit Kompression und Gehübungen für die meisten Fälle ausreicht, wird die zusätzliche Gabe von niedermolekularen Heparinen bei erhöhtem Thromboembolierisiko und bei Oberschenkelmitbeteiligung empfohlen. Die wenigen Studien berichten von einer Behandlungszeit von 6-12 Tagen. Mehr Studien speziell im Hinblick auf Indikation, Dosierung und Therapiedauer von NMH sind erforderlich, um klare Therapierichtlinien geben zu können.

Summary

The clinical diagnosis of superficial thrombophlebitis is characterized by the occurrence of painful and inflamed cords along superficial veins and varices. Duplex sonography is recommended to rule out asymptomatic deep vein thrombosis which may be present in about 20% and to check potential sources of entrance of the thrombotic process into deep veins, like the junctions of great and small saphenous veins.

Classic therapy is based on firm compression therapy and walking exercises. Incisions with expression of clots and anti-inflammatory drugs may reduce pain and inflammation. When phlebitis involves also the thigh and especially the proximal part of the great saphenous vein surgical ligation of the junction and local thrombectomy can be considered, preferably on an outpatient basis. Recent data from one randomised controlled trial demonstrate the efficacy of unfractionated heparin in a dose of 12 500 I.U. s. c. twice a day in this indication. According to another randomised controlled trial low molecular weight heparin (LMWH) may reduce the development of thromboembolic complications and also the relatively frequent extension of the thrombi in the superficial veins. Therapeutic doses seem to be more effective than prophylactic doses. While conventional therapy with compression and walking is sufficient for the majority of cases, the additional use of low molecular heparin is recommended in increased thromboembolic risk and when the thigh is involved. In the few studies available treatment time of 6-12 days is reported. More studies with special focus on indication, dosage and duration of therapy with LMWH are needed for the recommendation of clear therapeutic guidelines.

 
  • Literatur

  • 1 Ascer E, Lorensen E, Pollina RM, Gennaro M. Preliminary results of a nonoperative approach to saphenofemoral junction thrombophlebitis. J Vasc Surg 1995; 22: 616-21.
  • 2 Belcaro G, Nicolaides AN, Errichi BM, Cesarone MR, De Sanctis MT, Incandela L, Venniker R. Superficial thrombophlebitis of the legs: a randomized, controlled, follow-up study. Angiology 1999; 50: 523-9.
  • 3 Bergqvist D, Jaroszewski H. Deep vein thrombosis in patients with superficial thrombophlebitis of the leg. Br Med J (Clin Res Ed) 1986; 292: 658-9.
  • 4 Bergqvist D, Brunkwall J, Jensen N, Persson NH. Treatment of superficial thrombophlebitis. A comparative trial between placebo, hirudoid cream and piroxicam gel. Ann Chir Gynaecol 1990; 79: 92-6.
  • 5 Blättler W, Frick E. Complications of superficial thrombophlebitis. Schweiz Med Wochenschr 1993; 123: 223-8.
  • 6 Blumenberg RM, Barton E, Gelfand ML, Skudder P, Brennan J. Occult deep venous thrombosis complicating superficial thrombophlebitis. J Vasc Surg 1998; 27: 338-43.
  • 7 Bounameaux H, Reber-Wasem MA. Superficial thrombophlebitis and deep vein thrombosis. A controversial association. Arch Intern Med 1997; 157: 1822-4.
  • 8 Chengelis DL, Bendick PJ, Glover JL, Brown OW, Ranval TJ. Progression of superficial venous thrombosis to deep vein thrombosis. J Vasc Surg 1996; 24: 745-9.
  • 9 de Godoy JM, Batigalia F, Braile DM. Superficial thrombophlebitis and anticardiolipin antibodies – report of association. Angiology 2001; 52: 127-9.
  • 10 Decousus H. Treatment of superficial – vein thrombosis: a randomised double-blind comparison of low-molecular-weight heparin, non-steroidal anti-inflammatory agent and placebo. Thromb Haemost. 2001 (Suppl; ISSN 0340-6245).
  • 11 Downing LJ, Strieter RM, Kadell AM, Wilke CA, Greenfield LJ, Wakefield TW. Low-dose low-molecular-weight heparin is anti-inflammatory during venous thrombosis. J Vasc Surg 1998; 28: 848-54.
  • 12 Hanson JN, Ascher E, DePippo P, Lorensen E, Scheinman M, Yorkovich W, Hingorani A. Saphenous vein thrombophlebitis (SVT): a deceptively benign disease. J Vasc Surg 1998; 27: 677-80.
  • 13 Jorgensen JO, Hanel KC, Morgan AM, Hunt JM. The incidence of deep venous thrombosis in patients with superficial thrombophlebitis of the lower limbs. J Vasc Surg 1993; 18: 70-3.
  • 14 Krause U, Kock HJ, Kroger K, Albrecht K, Rudofsky G. Prevention of deep venous thrombosis associated with superficial thrombophlebitis of the leg by early saphenous vein ligation. Vasa 1998; 27: 34-8.
  • 15 Leu HJ. Thrombosis and phlebitis of superficial veins. Differential histopathologic diagnosis. Pathologe 1995; 16: 386-90.
  • 16 Leu HJ. Phlebitides – a survey. Vasa 1994; 23: 289-98.
  • 17 Ligush Jr J, Johnson Jr G. Superficial thrombophlebitis. In: Gloviczki P, Yao JST. (eds). Handbook of Venous Disorders. London: Chapman and Hall Medical; 1996: 235-42.
  • 18 Lutter KS, Kerr TM, Roedersheimer LR, Lohr JM, Sampson MG, Cranley JJ. Superficial thrombophlebitis diagnosed by duplex scanning. Surgery 1991; 110: 42-6.
  • 19 Marchiori A, Verlato F, Sabbion P, Camporese G, Rosso F, Mosena L, Andreozzi GM, Prandoni P. High versus low doses of unfractionated heparin for the treatment of superficial thrombophlebitis of the leg. A prospective, controlled, randomized study. Haematologica 2002; 87: 523-7.
  • 20 Mayer W, Partsch H. Superficial phlebitis: a harmless disorder?. Scope Phlebol 1999; 6: 36-8.
  • 21 McColl MD, Ramsay JE, Tait RC, Walker ID, McCall F, Conkie JA, Carty MJ, Greer IA. Superficial vein thrombosis: incidence in association with pregnancy and prevalence of thrombophilic defects. Thromb Haemost 1998; 79: 741-2.
  • 22 Mehta PP, Sagar S, Kakkar VV. Treatment of superficial thrombophlebitis: a randomized, double-blind trial of heparinoid cream. Br Med J 1975; 3: 614-6.
  • 23 Morselli-Lanz B. Progredienz der Varikosis. Thesis Universität Basel; 1992
  • 24 Murgia AP, Cisno C, Pansini GC, Manfredini R, Liboni A, Zamboni P. Surgical management of ascending saphenous thrombophlebitis. Int Angiol 1999; 18: 343-7.
  • 25 Partsch H, Mostbeck A. Lungenembolien bei oberflächlicher Thrombophlebitis?. Acta Med Aust 1979; 6: 159-60.
  • 26 Partsch H, Menzinger G, Groiss E, Borst-Krafek B. Does thigh compression improve venous haemodynamics in chronic venous insufficiency?. J Vasc Surg. DOI: 10.1067/mva 2002: 127343.
  • 27 Prountjos P, Bastounis E, Hadjinikolaou L, Felekuras E, Balas P. Superficial venous thrombosis of the lower extremities co-existing with deep venous thrombosis. A phlebographic study on 57 cases. Int Angiol 1991; 10: 63-5.
  • 28 Samlaska CP, James WD. Superficial thrombophlebitis. I. Primary hypercoagulable states. J Am Acad Dermatol 1990; 22: 975-89.
  • 29 Schönauer V, Kyrle PA, Weltermann A, Minar E, Bialonczyk C, Hirschl M, Quehenberger P, Schneider B, Partsch H, Eichinger S. Superficial vein thrombosis and the risk of recurrent venous thromboembolism. J. Vasc Surg. (in print).
  • 30 Skillman JJ, Kent KC, Porter DH, Kim D. Simultaneous occurrence of superficial and deep thrombophlebitis in the lower extremity. J Vasc Surg 1990; 11: 818-23.
  • 31 Sullivan V, Denk PM, Sonnad SS, Eagleton MJ, Wakefield TW. Ligation versus anticoagulation: treatment of above-knee superficial thrombophlebitis not involving the deep venous system. J Am Coll Surg 2001; 193: 556-62.
  • 32 Titon JP, Auger D, Grange P, Hecquet JP, Remond A, Ulliac P, Vaissie JJ. Therapeutic management of superficial venous thrombosis with calcium nadroparin. Dosage testing and comparison with a non-steroidal anti-inflammatory agent. Ann Cardiol Angiol (Paris) 1994; 43: 160-6.
  • 33 Verlato F, Zucchetta P, Prandoni P, Camporese G, Marzola MC, Salmistraro G, Bui F, Martini R, Rosso F, Andreozzi GM. An unexpectedly high rate of pulmonary embolism in patients with superficial thrombophlebitis of the thigh. J Vasc Surg 1999; 30: 1113-5.
  • 34 Widmer LK, Stähelin HB, Nissen C, da Silva A. Venen-, Arterien-Krankheiten, koronare Herzkrankheit bei Berufstätigen. Prospektiv-epidemiologische Untersuchung, Basler Studie I-III 1959-1978. Bern: Hans Huber; 1981